Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia

被引：2
|
作者：
Tadmor, Tamar [1 ,2 ]
Yurkovski, Ilana Levy [1 ,2 ]
机构：
[1] Bnai Zion Med Ctr, Hematol Unit, Golomb 47 St, IL-31048 Haifa, Israel
[2] Technion Int Inst Technol, Rappaport Fac Med, Haifa, Israel
来源：
LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 05期
关键词：
PHASE-II; CLADRIBINE; RITUXIMAB; DIAGNOSIS; GUIDELINES; BRAF;
D O I：
10.1080/10428194.2024.2304026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：684 / 687
页数：4
相关论文
共 50 条
  • [1] Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma
    Buske, Christian
    LANCET ONCOLOGY, 2022, 23 (08): : 967 - 969
  • [2] EFFICACY OF RITUXIMAB-THERAPY IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA
    Cheveresan, L.
    Cheveresan, M.
    Ionta, H.
    Nicola, D.
    Calamar, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 527 - 527
  • [3] Rituximab in relapsed or refractory hairy cell leukemia
    Thomas, DA
    O'Brien, S
    Bueso-Ramos, C
    Faderl, S
    Keating, MJ
    Giles, FJ
    Cortes, J
    Kantarjian, HM
    BLOOD, 2003, 102 (12) : 3906 - 3911
  • [4] Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia
    Cross, Matthew J.
    Shah, Paras
    Heelan, Kara
    Dearden, Claire E.
    El-Sharkawi, Dima
    Iyengar, Sunil
    BLOOD, 2020, 136
  • [5] Patients with relapsed/refractory hairy-cell leukemia
    Paillassa, Jerome
    Troussard, Xavier
    CANCER REPORTS, 2022, 5 (03)
  • [6] Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
    Robert J. Kreitman
    Claire Dearden
    Pier Luigi Zinzani
    Julio Delgado
    Lionel Karlin
    Tadeusz Robak
    Douglas E. Gladstone
    Philipp le Coutre
    Sascha Dietrich
    Mirjana Gotic
    Loree Larratt
    Fritz Offner
    Gary Schiller
    Ronan Swords
    Larry Bacon
    Monica Bocchia
    Krimo Bouabdallah
    Dimitri A. Breems
    Agostino Cortelezzi
    Shira Dinner
    Michael Doubek
    Bjorn Tore Gjertsen
    Marco Gobbi
    Andrzej Hellmann
    Stephane Lepretre
    Frederic Maloisel
    Farhad Ravandi
    Philippe Rousselot
    Mathias Rummel
    Tanya Siddiqi
    Tamar Tadmor
    Xavier Troussard
    Cecilia Arana Yi
    Giuseppe Saglio
    Gail J. Roboz
    Kemal Balic
    Nathan Standifer
    Peng He
    Shannon Marshall
    Wyndham Wilson
    Ira Pastan
    Nai-Shun Yao
    Francis Giles
    Leukemia, 2018, 32 : 1768 - 1777
  • [7] Ibrutinib for relapsed refractory hairy cell leukemia variant
    Bohn, Jan-Paul
    Wanner, David
    Steurer, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 (05) : 1224 - 1226
  • [8] Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
    Tam, Constantine S.
    Trotman, Judith
    Opat, Stephen
    Stern, Jennifer C.
    Allewelt, Heather
    By, Kunthel
    Novotny, William
    Huang, Jane
    Tedeschi, Alessandra
    BLOOD ADVANCES, 2023, 7 (12) : 2884 - 2887
  • [9] Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia
    Tiacci, Enrico
    De Carolis, Luca
    Santi, Alessia
    Falini, Brunangelo
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (10): : 952 - 954
  • [10] Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
    Burotto, Mauricio
    Stetler-Stevenson, Maryalice
    Arons, Evgeny
    Zhou, Hong
    Wilson, Wyndham
    Kreitman, Robert J.
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6313 - 6321
12345